Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence

Trial Profile

Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Stress incontinence
  • Focus Adverse reactions
  • Sponsors GTx
  • Most Recent Events

    • 27 Sep 2018 Status changed from recruiting to discontinued due to lack of efficacy
    • 26 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 29 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top